Pfizer Inc. or Lantheus Holdings, Inc.: Who Leads in Yearly Revenue?

Pfizer vs. Lantheus: Revenue Growth Battle

__timestampLantheus Holdings, Inc.Pfizer Inc.
Wednesday, January 1, 201430160000049605000000
Thursday, January 1, 201529346100048851000000
Friday, January 1, 201630185300052824000000
Sunday, January 1, 201733137800052546000000
Monday, January 1, 201834337400053647000000
Tuesday, January 1, 201934733700051750000000
Wednesday, January 1, 202033941000041908000000
Friday, January 1, 202142520800081288000000
Saturday, January 1, 2022935061000100330000000
Sunday, January 1, 2023129642900058496000000
Loading chart...

Infusing magic into the data realm

Pfizer vs. Lantheus: A Revenue Showdown

In the ever-evolving pharmaceutical landscape, revenue growth is a key indicator of a company's market position and potential. Over the past decade, Pfizer Inc. has consistently outpaced Lantheus Holdings, Inc. in annual revenue. From 2014 to 2023, Pfizer's revenue surged by approximately 20%, peaking in 2022 with a staggering 100% increase compared to its 2014 figures. In contrast, Lantheus Holdings, Inc. experienced a more modest growth, with its revenue increasing by over 300% during the same period, reaching its zenith in 2023.

While Pfizer's revenue in 2022 was nearly 100 times that of Lantheus, the latter's rapid growth trajectory is noteworthy. This data highlights the contrasting scales and growth dynamics of these two industry players, offering insights into their strategic directions and market impacts.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025